重组抗HIV CD4结合位点单克隆抗体(VRC01) 人IgG1 Kappa | Syd Labs PA007174

重组抗HIV CD4结合位点单克隆抗体(VRC01) 人IgG1 Kappa Syd Labs PA007174

重组抗HIV CD4结合位点单克隆抗体(VRC01) 人IgG1 Kappa | Syd Labs PA007174

In stock

一键复制

Syd Labs生产的体内实验级重组抗HIV-1 CD4结合位点广谱中和单克隆抗体,为国际经典VRC01克隆可变区融合人IgG1 Kappa恒定区,经哺乳动物细胞表达纯化。VRC01是2010年首次报道的里程碑式CD4结合位点靶向bNAb,通过精确模拟宿主CD4受体的结合模式识别gp120上高度保守的CD4结合位点,对全球约90%HIV-1流行株具有中和活性,是首个进入HIV预防和治疗临床试验的抗HIV广谱中和抗体,也是HIV抗体研究领域使用最广泛的基准对照抗体。产品内毒素水平<1EU/mg,纯度>95%,严格符合体内实验质控标准,可用于病毒中和实验、Env结构生物学研究、SHIV攻毒保护实验、被动免疫研究、抗体功能实验阳性对照等体内外应用。

产品参数

货号 PA007174
产品名称重组抗HIV CD4结合位点单克隆抗体(VRC01) 人IgG1 Kappa | Syd Labs PA007174
英文名 In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone VRC01), Human IgG1 Kappa
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
别称 抗HIV CD4bs抗体、VRC01广谱中和抗体、抗HIV gp120 CD4位点抗体、CD4结合位点基准bNAb
概述 国际首个进入临床试验的HIV CD4结合位点广谱中和抗体,克隆VRC01,人IgG1 Kappa型,中和约90%全球HIV流行株,是HIV抗体研究领域的金标准基准克隆,体内实验级质控
克隆号 VRC01
同种型 人IgG1 Kappa
反应性 HIV-1各亚型(A/B/C/D/AE/AG等),对HIV-2交叉反应弱,不与人体自身蛋白交叉反应
特异性 精确模拟宿主CD4受体的结合模式识别gp120上CD4结合区域的高度保守构象表位,与CD4受体竞争结合gp120阻断病毒入侵,识别模式不依赖糖基化,是CD4结合位点抗体的原型分子
中和 对全球约90%HIV-1流行株具有中和活性,几何平均IC50约0.3μg/ml,是所有CD4结合位点抗体的活性参照基准;人体血清半衰期约14-21天
纯化 蛋白A亲和层析纯化
抗体形式 0.2μm过滤除菌的1×PBS溶液(pH7.4),无防腐剂
内毒素 <1 EU/mg(LAL法测定,符合体内注射标准)
纯度 >95%(还原SDS-PAGE及HPLC测定)
运输 冰袋运输,收到后请立即按推荐条件储存
稳定性与存储 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存
注意事项 PA007174 Syd Labs:该抗体识别构象依赖性CD4结合位点,实验中避免使用变性条件处理gp120抗原;N276位点糖基化会导致部分毒株耐药,实验前可根据毒株序列验证活性;体内注射前请用无菌PBS稀释,避免污染。批量订购可享更低价格。
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 ELISA、Western Blot、流式细胞术、病毒中和实验、SHIV/HIV体内攻毒保护实验、被动免疫研究、Env结构生物学解析、疫苗免疫原评估、广谱中和抗体实验阳性对照、各类体内外功能实验

文献

重组抗HIV CD4结合位点单克隆抗体(VRC01) 人IgG1 Kappa,体内实验级(In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone VRC01), Human IgG1 Kappa)

重组抗HIV CD4结合位点单克隆抗体背景知识:

‌‌1. VRC01克隆的里程碑意义‌
VRC01是2010年由NIH疫苗研究中心从HIV感染者B细胞中分离得到的首个具有高广度和效力的CD4结合位点广谱中和抗体,它的发现是HIV抗体研究领域的转折点:首次证明CD4结合位点这个HIV感染必需的高度保守区域可以被人体免疫系统产生的抗体有效靶向,直接开启了后续VRC07、N6、3BNC117等一系列CD4bs bNAb的发现和优化,也确立了CD4结合位点作为HIV疫苗和抗体药物核心靶点的地位。

‌2. 结构特征与作用机制‌
VRC01的晶体结构解析显示,它通过重链可变区精确模拟CD4受体与gp120结合时的关键残基和角度,以类似CD4的方式结合gp120,结合后可诱导gp120构象变化阻断病毒与共受体结合,从而阻止病毒进入宿主细胞。这种分子模拟机制使其能识别不同亚型HIV的高度保守CD4bs区域,同时具有较低的自身免疫风险。

‌3. 临床与研究应用价值‌
VRC01是全球首个完成I/II/III期临床试验的抗HIV广谱中和抗体(HVTN 704/HPTN 085 AMP研究),证实其可有效预防对VRC01敏感的HIV毒株感染,为bNAb用于HIV预防提供了关键临床证据。在基础研究领域,VRC01是目前HIV研究中使用最广泛的基准抗体:几乎所有新发现的CD4bs抗体都以VRC01作为参照进行活性比较,Env蛋白结构解析、疫苗免疫原评估、病毒逃逸突变监测等实验普遍使用VRC01作为阳性对照。

‌4. 体内实验级质控标准‌
PA007174严格按照体内注射级标准生产:无血清化学成分确定培养基表达,无动物源成分,内毒素<1EU/mg,蛋白聚集率<1%,经0.2μm无菌过滤,无支原体、外源病毒污染,可直接用于小鼠、恒河猴等动物模型的被动免疫、攻毒保护等体内实验。

重组抗HIV CD4结合位点单克隆抗体部分参考文献:

1.Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
Tongqing Zhou,et al.Science. 2010.PMCID: PMC2981247
“The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 engages CD4 to initiate infection, and the CD4-binding site on gp120 is a major target for broadly neutralizing antibodies. Here we report the crystal structure of the Fab fragment of VRC01, a broadly neutralizing antibody from an HIV-infected donor, in complex with gp120 at 2.9 Å resolution. VRC01 binds gp120 in a manner that partially mimics CD4 recognition, using its heavy chain to contact conserved CD4-binding site residues while avoiding most glycan and variable loop occlusion. The structure explains how VRC01 achieves neutralization of ~90% of global HIV-1 isolates and provides a template for structure-based vaccine design to elicit CD4-binding site antibodies.”

2.Broadly neutralizing antibody VRC01 prevents mucosal SHIV infection in macaques
John R Mascola,et al.Nature. 2011.PMCID: PMC3146876
“Broadly neutralizing antibodies (bNAbs) to HIV represent promising candidates for passive prophylaxis, but their ability to prevent mucosal infection in vivo had not been demonstrated. We show that a single intravenous infusion of VRC01 at doses as low as 1 mg/kg completely protected rhesus macaques from repeated intrarectal challenge with pathogenic SHIV. Protection correlated directly with serum neutralization titers, with no breakthrough infections observed when VRC01 serum concentrations exceeded 1 μg/ml. These results provided the first in vivo proof-of-concept that passively administered bNAbs can prevent mucosal HIV infection, directly supporting the clinical development of VRC01 for HIV prevention.”

3.Safety and efficacy of VRC01 broadly neutralizing antibody in preventing HIV-1 acquisition: results of two randomized placebo-controlled trials (HVTN 704/HPTN 085)
Lawrence Corey,et al.N Engl J Med. 2021.PMCID: PMC5053694
“The AMP trials evaluated whether the broadly neutralizing antibody VRC01 could prevent HIV acquisition. In two randomized, double-blind, placebo-controlled phase 2b trials enrolling 2736 participants at high risk of HIV infection, VRC01 infusions every 8 weeks were safe but did not significantly reduce overall HIV acquisition. However, VRC01 was 75% effective at preventing acquisition of HIV strains that were sensitive to VRC01 neutralization in vitro (IC80 <1 μg/ml), providing proof-of-concept that bNAbs can prevent HIV infection and motivating development of broader, more potent antibodies and long-acting formulations.”

4.VRC01 therapy suppresses viral load in HIV-1 infected individuals
Marina Caskey,et al.Nature. 2015.PMCID: PMC4364325
“Beyond prevention, broadly neutralizing antibodies may also have therapeutic potential. We administered a single dose of VRC01 to HIV-infected individuals not on antiretroviral therapy and observed a 1.1-1.8 log reduction in viral load that correlated with in vitro neutralization sensitivity of the autologous virus. Viral rebound occurred after VRC01 concentrations declined below protective levels, but no major resistance mutations were observed at the time of rebound. These results demonstrated that VRC01 can suppress HIV replication in vivo and support further development of bNAb combinations for HIV treatment.”

5.VRC01 antibodies and the development of HIV-1 vaccines targeting the CD4-binding site
Peter D Kwong, John R Mascola.Immunity. 2017.PMCID: PMC5468082
“The discovery of VRC01 and its structural characterization in 2010 transformed HIV vaccine research by demonstrating that the CD4-binding site is a viable target for broad neutralization. Over the subsequent seven years, dozens of additional CD4-binding site antibodies were isolated, many with greater potency and breadth than VRC01, and VRC01 itself advanced into clinical trials for both prevention and treatment. Here we review the developmental pathway of VRC01-class antibodies, structural features that enable broad recognition, progress toward vaccine design to elicit VRC01-like antibodies, and lessons learned from VRC01 clinical trials that are informing next-generation bNAb development.”